FDA
label_change
· 2021-04-07
FDA Approved: EXFORGE — Supplemental Application (Novartis Pharmaceuticals Corporation)
Summary
The FDA approved a supplemental application for EXFORGE (amlodipine besylate and valsartan) filed by Novartis, updating the product labeling.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for EXFORGE (AMLODIPINE BESYLATE AND VALSARTAN)